Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v5-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2020-03-10 | 2020-02-13 |
Drug Identification Number | 02381842 | 02381842 |
Brand name | TAMIFLU | TAMIFLU |
Common or Proper name | Oseltamivir Phosphate | Oseltamivir Phosphate |
Company Name | HOFFMANN-LA ROCHE LIMITED | HOFFMANN-LA ROCHE LIMITED |
Ingredients | OSELTAMIVIR | OSELTAMIVIR |
Strength(s) | 6MG | 6MG |
Dosage form(s) | POWDER FOR SUSPENSION | POWDER FOR SUSPENSION |
Route of administration | ORAL | ORAL |
Packaging size | 100 mL glass bottles with a bottle adapter and 1 oral dispenser | 100 mL glass bottles with a bottle adapter and 1 oral dispenser |
ATC code | J05AH | J05AH |
ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
Anticipated start date | 2020-03-01 | 2020-03-01 |
Actual start date | 2020-03-10 | |
Estimated end date | 2020-03-31 | 2020-03-31 |
Actual end date | ||
Shortage status | Anticipated shortage | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Roche will manage the supply of current inventory until the end of February. We anticipate availability of new stock by the end of March. | Roche will manage the supply of current inventory until the end of February. We anticipate availability of new stock by the end of March. |
Health Canada comments |